In the Lab: Re­gen­eron brings its an­ti­body chops to gene edit­ing's biggest prob­lem, aim­ing to 'change the field'

TAR­RY­TOWN, NY — For over three decades, Re­gen­eron has been syn­ony­mous with one thing in the drug in­dus­try: an­ti­bod­ies. Block­busters like Dupix­ent, Eylea, and Covid-19 an­ti­bod­ies have trans­formed what start­ed as a scrap­py start­up in­to one of biotech’s biggest names.

But the bil­lion­aire co-founders who still run the $91 bil­lion gi­ant, CEO Leonard Schleifer and CSO George Yan­copou­los, have spent near­ly the last decade work­ing on the com­pa­ny’s next act. They have part­nered, built, and bought their way in­to ge­net­ic med­i­cine, go­ing be­yond an­ti­bod­ies in­to CRISPR, RNA in­ter­fer­ence, and oth­er tech­nolo­gies that ma­nip­u­late the ge­net­ic code of life.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER